Type 2 diabetes mellitus (T2D) is one of the chronic epidemics with the greatest global impact: more than 537 million adults live with the disease worldwide, with a projection of 783 million by 2045. Chronic hyperglycemia causes progressive microvascular and macrovascular damage — retinopathy, nephropathy, peripheral neuropathy, and increased cardiovascular risk. Despite the available pharmacologic arsenal (metformin, SGLT-2 inhibitors, GLP-1 agonists, insulin), most patients do not reach recommended glycemic targets (HbA1c <7%), and the side effects of medications are a frequent cause of nonadherence. Acupuncture, through its mechanisms of neuroendocrine modulation and improvement of insulin sensitivity, represents an adjuvant therapy with growing biological plausibility. A meta-analysis published in Frontiers in Endocrinology in June 2025, gathering 21 RCTs with 2,117 patients, documents significant benefits in multiple glycemic markers.
The study searched for evidence in six databases — PubMed, Web of Science, Cochrane Library, Embase, CNKI, and Wanfang — with a cutoff date prior to publication in 2025. The inclusion of RCTs in both English and Chinese is methodologically important to avoid the publication bias that under-represents Asian research in Western databases. Only studies with a confirmed T2D diagnosis according to WHO or ADA criteria were included, with objective glycemic outcomes (HbA1c, fasting blood glucose, postprandial blood glucose, HOMA-IR, FINS). Secondary outcomes included BMI, lipid profile (HDL, LDL), and nerve conduction velocity — relevant given the impact of diabetic neuropathy.
META-ANALYSIS RESULTS OF ACUPUNCTURE FOR TYPE 2 DIABETES (FRONTIERS ENDOCRINOLOGY, JUN 2025)
Mechanisms: How Acupuncture Influences Glucose Metabolism
The biological plausibility of acupuncture in T2D is robust and multimodal. The acupoint ST-36 (Zusanli), one of the most studied in basic research, may activate cholinergic anti-inflammatory pathways via the vagus nerve — the same mechanism by which GLP-1 agonists (such as semaglutide) increase insulin sensitivity and reduce systemic inflammation. Studies in animal models of type 2 diabetes have suggested that ST-36 stimulation increases GLUT-4 expression in skeletal muscle (the principal insulin-dependent glucose transporter), reduces hepatic glucose production, and increases muscle glycogen synthesis — three central mechanisms in glycemic control. These findings derive from experimental models and require confirmation in human clinical studies.
Acupuncture has also been proposed as a modulator of the hypothalamic–pituitary–adrenal (HPA) axis: hyperactivity of the HPA axis — common in patients with T2D and diabetes under chronic stress — raises cortisol, which in turn induces hyperglycemia and insulin resistance. Modulation of autonomic tone by acupuncture may reduce chronic sympathetic activity, decreasing levels of cortisol and catecholamines — which indirectly improves insulin sensitivity. This neuroendocrine mechanism is complementary to that of metformin (which acts mainly by reducing hepatic glucose production through AMPK activation) and may have a synergistic effect when therapies are combined.
Secondary Outcomes: Lipids, BMI, and Neuropathy
In addition to the primary glycemic outcomes, the meta-analysis documented benefits in secondary outcomes. BMI showed significant reduction — consistent with mechanisms of modulation of appetite and energy expenditure by acupuncture (also relevant in articles on electroacupuncture and vagal GLP-1 published on this site). The lipid profile — with improvement of HDL and reduction of LDL — reflects the overall metabolic impact of acupuncture on the metabolic syndrome that frequently accompanies T2D. The data on nerve conduction velocity is particularly relevant: patients with diabetic neuropathy showed improvement in motor and sensory conduction velocity — an objective functional outcome that goes beyond laboratory markers and that has direct implication for quality of life and risk of diabetic ulcer.
Heterogeneity across the studies was substantial for some indicators — the authors acknowledge that the diversity of acupuncture protocols (session frequency, acupoints selected, use of electroacupuncture vs. manual, association with moxibustion) contributes to that variability. This limitation is also an opportunity: future RCTs with standardized protocols could generate more precise effect estimates and identify which patient subgroups (by disease stage, medications used, TCM diagnostic pattern) benefit most.
Frequently Asked Questions
The RCTs in this meta-analysis were not designed to evaluate medication reduction — they evaluated the effects of acupuncture on glycemic markers, keeping medications stable. What the data suggest is that acupuncture may improve glycemic control when added to current pharmacologic treatment. If, over time, this allows a review of medication doses, that decision should be made by the endocrinologist based on HbA1c and glycemia values — never autonomously by the patient, especially in the case of insulin.
The studies in this meta-analysis included exclusively patients with T2D. Type 1 diabetes has a completely different pathophysiology — autoimmune destruction of pancreatic beta cells, with absolute insulin deficiency — and the role of acupuncture in this context is distinct. There is preliminary evidence that acupuncture may reduce glycemic variability and improve quality of life in T1D, possibly via modulation of the autonomic axis and reduction of oxidative stress. But there is no meta-analysis of well-designed RCTs for T1D — the management of this condition remains centered on intensive insulin therapy.
Based on the RCTs included in this meta-analysis, the most common protocol was 3 sessions per week for 8–12 weeks. The improvement in HbA1c — which reflects average glycemia over the past 3 months — takes at least 6–8 weeks to manifest in laboratory values. Fasting glucose and postprandial glucose respond more quickly, and improvements are possible in the first 4 weeks. For maintenance of benefits, monthly or biweekly sessions after the intensive phase are a reasonable strategy, similar to what is done in other chronic conditions treated with acupuncture.
Founded in 1989 by physicians trained at the University of São Paulo (USP) and specialized in China, CEIMEC is a Brazilian national reference in the teaching and practice of medical acupuncture. With more than 3,000 physicians trained over 35 years, it collaborates with HC-FMUSP and is recognized by the Brazilian Medical College of Acupuncture (CMBA/AMB).